Literature DB >> 11818620

Pheochromocytomas: detection with 18F DOPA whole body PET--initial results..

Stefan Hoegerle1, Egbert Nitzsche, Carsten Altehoefer, Nadir Ghanem, Tanja Manz, Ingo Brink, Martin Reincke, Ernst Moser, Hartmut P H Neumann.   

Abstract

PURPOSE: To evaluate fluorine 18 ((18)F) dihydroxyphenylalanine (DOPA) whole-body positron emission tomography (PET) as a biochemical imaging approach for detection of pheochromocytomas.
MATERIALS AND METHODS: (18)F DOPA PET and magnetic resonance (MR) imaging were performed in 14 consecutive patients suspected of having pheochromocytomas (five sporadic, nine with von Hippel-Lindau disease); metaiodobenzylguanidine (MIBG) scintigraphy was performed in 12 of these patients. The individual imaging findings were assessed in consensus by specialists in nuclear medicine and radiologists blinded to the results of the other methods. The findings of the functional imaging methods were compared with those of MR imaging, the reference standard. Histologic verification could be obtained in eight patients with nine tumors.
RESULTS: Seventeen pheochromocytomas (11 solitary, three bifocal; 14 adrenal, three extraadrenal) were detected with MR imaging. (18)F DOPA PET and MR imaging had concordant results in all 17 tumors. In contrast, MIBG scintigraphy had false-negative results in four patients with three adrenal tumors smaller than 2 cm and one extraadrenal tumor with a diameter of 3.6 cm. On the basis of these data, sensitivities of 100% for (18)F DOPA PET and of 71% for MIBG scintigraphy were calculated. Specificity was 100% for both procedures.
CONCLUSION: (18)F DOPA PET is highly sensitive and specific for detection of pheochromocytomas and has potential as the functional imaging method of the future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11818620     DOI: 10.1148/radiol.2222010622

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  68 in total

1.  Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.

Authors:  Arnoldo Piccardo; Egesta Lopci; Massimo Conte; Alberto Garaventa; Luca Foppiani; Vania Altrinetti; Cristina Nanni; Pietro Bianchi; Angela Cistaro; Stefania Sorrentino; Manlio Cabria; Andrea Pession; Matteo Puntoni; Giampiero Villavecchia; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

2.  Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.

Authors:  Alexander Kroiss; Daniel Putzer; Christian Uprimny; Clemens Decristoforo; Michael Gabriel; Wolfram Santner; Christof Kranewitter; Boris Warwitz; Dietmar Waitz; Dorota Kendler; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-29       Impact factor: 9.236

3.  18F-DOPA PET/CT and neuroendocrine tumours.

Authors:  Cristina Nanni; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05       Impact factor: 9.236

4.  MIBG-SPECT/CT-angiography with 3-D reconstruction of an extra-adrenal phaeochromocytoma with dissection of an aortic aneurysm.

Authors:  Klaus Strobel; C Burger; P Schneider; M Weber; Thomas F Hany
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01       Impact factor: 9.236

Review 5.  The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review.

Authors:  Juan P Brito; Noor Asi; Michael R Gionfriddo; Catalina Norman; Aaron L Leppin; Claudia Zeballos-Palacios; Chaitanya Undavalli; Zhen Wang; Juan P Domecq; Gabriela Prustsky; Tarig A Elraiyah; Larry J Prokop; Victor M Montori; Mohammad Hassan Murad
Journal:  Endocrine       Date:  2015-02-06       Impact factor: 3.633

6.  Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.

Authors:  Kathryn S King; Clara C Chen; Dimitrios K Alexopoulos; Millie A Whatley; James C Reynolds; Nicholas Patronas; Alexander Ling; Karen T Adams; Paraskevi Xekouki; Howard Lando; Constantine A Stratakis; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2011-07-13       Impact factor: 5.958

7.  Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO).

Authors:  Henri J L M Timmers; Graeme Eisenhofer; Jorge A Carrasquillo; Clara C Chen; Millie Whatley; Alexander Ling; Karen T Adams; Karel Pacak
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-05       Impact factor: 3.478

8.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

9.  [Adrenal tumors: principles of imaging and differential diagnostics].

Authors:  C Degenhart
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

Review 10.  Current and future trends in the anatomical and functional imaging of head and neck paragangliomas.

Authors:  David Taïeb; Arthur Varoquaux; Clara C Chen; Karel Pacak
Journal:  Semin Nucl Med       Date:  2013-11       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.